Using beta-blockers for heart attack patients in intensive care
Early Beta-Blocker Administration in Patients With ST Segment Elevation Myocardial Infraction and SCAI B Status
This study is testing if the heart medication metoprolol can help heart attack patients in intensive care feel better and avoid worsening their condition.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tel-Aviv Sourasky Medical Center Government |
| Locations | 1 site (Tel Aviv) |
| Trial ID | NCT06967194 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of the beta-blocker metoprolol on patients diagnosed with ST-segment elevation myocardial infarction (STEMI) who are classified as SCAI B upon admission to the cardiac intensive care unit. Patients will be randomly assigned to receive either metoprolol or a placebo for a duration of 72 hours, with continuous monitoring of vital signs and lactate levels. The primary goal is to determine if metoprolol can improve patient outcomes or prevent deterioration in their condition. Safety is prioritized, allowing for the study to be halted if necessary.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with STEMI and classified as SCAI B upon admission.
Not a fit: Patients with conditions such as pregnancy, severe bradycardia, or known hypersensitivity to metoprolol may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could improve recovery outcomes for heart attack patients in critical condition.
How similar studies have performed: Previous studies have shown promising results with beta-blocker administration in similar patient populations, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of ST-segment elevation myocardial infarction (STEMI) confirmed by ECG, clinical signs, and coronary catheterization. * Post-catheterization patients classified as SCAI B upon admission to the unit, defined by the presence of tachycardia and/or hypotension without signs of hypoperfusion (i.e., normal lactate levels, normal capillary refill, preserved mental status, and adequate urine output \>0.5 mL/kg/hour). * Age 18 years or older. * Mentally competent to provide informed consent, understand the study procedures, and comply with medical recommendations. Exclusion Criteria: * Pregnancy. * Inability to provide informed consent. * Evidence of pulmonary edema. * Bradycardia (heart rate \<60 beats per minute). * PR interval \>240 milliseconds. * Second- or third-degree atrioventricular (AV) block. * Active asthma. * Known hypersensitivity to metoprolol.
Where this trial is running
Tel Aviv
- Tel Aviv Sourasky Medical center — Tel Aviv, Israel (Recruiting)
Study contacts
- Principal investigator: Yishay Szekely, MD — Tel-Aviv Sourasky Medical Center
- Study coordinator: Shir Frydman, MD
- Email: shirfrydman@gmail.com
- Phone: 0544267898
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.